Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma

NCT00220285 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma
Lymphoma, B-Cell
Lymphoma, Low-Grade

Interventions

DRUG: Zevalin (SH L 749 , BAY86-5128)
DRUG: Zevalin (SH L 749 , BAY86-5128)

Sponsor

Bayer